Celltrion Group Introduces Remsima SC and Uplyma at the European Crohn's and Colitis Organisation Congress

[Asia Economy Reporter Lee Gwan-ju] Celltrion Group announced on the 7th that it will participate in the '2022 United European Gastroenterology Week (UEGW)' held from the 8th to the 11th (local time) in Vienna, Austria, to showcase the competitiveness of autoimmune disease treatments such as Remsima SC and Yuflyma.

UEGW is the largest gastroenterology-related conference in Europe, where the latest clinical research and trends in drug development related to gastrointestinal diseases such as stomach cancer, inflammatory bowel disease, and immunology are presented. This year, it is held simultaneously on-site in Vienna, Austria, and online.

At this UEGW, Celltrion Group will hold a symposium on the theme of "The potential of subcutaneous infliximab as a biobetter in inflammatory bowel disease," presenting clinical data and real-world data of Remsima SC. In addition, Celltrion Healthcare will open a dedicated promotional booth on-site and conduct seminars introducing the competitiveness of Remsima SC and Yuflyma.

Remsima SC (left) and Uplima.
Photo by Celltrion

Remsima SC is a product developed as a subcutaneous (SC) formulation of infliximab, which is widely used in the TNF-α (tumor necrosis factor) inhibitor market. It has completed patent applications for formulation and administration methods in more than 130 countries worldwide, securing an exclusive position for about 20 years. Recently, in Europe, it has been evaluated as successfully entering the market by achieving a 9.1% market share in the first quarter of this year within two years of its launch, with strengths in rapid dosing effect and formulation convenience.

Yuflyma is the world's first high-concentration Humira biosimilar approved by the European Medicines Agency (EMA), authorized for all indications held by the original drug Humira and currently supplied in Europe. Celltrion recently received approval from regulatory agencies in the United States and Europe for a global Phase 3 clinical trial plan to secure 'interchangeability' with the original drug Humira and has begun full-scale clinical trials.

A Celltrion Group official said, "Following the strong performance of Remsima in the European autoimmune disease treatment market, Remsima SC and Yuflyma, regarded as next-generation growth engines, are also showing stable growth. Since both products have proven their efficacy and safety not only in global clinical trials but also in actual prescription data, the group plans to spare no effort to ensure they are more widely used by European patients and medical professionals."